Second-line chemotherapy for advanced hormone-refractory prostate cancer

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 2, 2008, Pages 118-132

  Garmey, Edward G ^a   Sartor, Oliver ^b   Halabi, Susan ^c   Vogelzang, Nicholas J ^d  

^a ARQULE INC   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NEVADA CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Hormone refractory prosate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CARBOPLATIN; CELECOXIB; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DNA; DOCETAXEL; EPIRUBICIN; ESTRAMUSTINE; ESTROGEN DERIVATIVE; GLUCOCORTICOID; GONADORELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IXABEPILONE; IXEMPRA; KETOCONAZOLE; MITOXANTRONE; OXALIPLATIN; PA 2024; PACLITAXEL; PLACEBO; PREDNISONE; PROVENGE; RADIOISOTOPE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; CANCER INCIDENCE; CANCER MORTALITY; CARDIOMYOPATHY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DNA SYNTHESIS INHIBITION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG POTENTIATION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INFECTION; INTESTINE OBSTRUCTION; LETHARGY; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; ORCHIECTOMY; OVERALL SURVIVAL; PROGNOSIS; PROSTATE CANCER; PROTHROMBIN TIME; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY;

EID: 41749086924     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program Oncologist. 2007;12:20-37.
2. Armstrong AJ, Garrett-Mayer ES, Yang VC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13: 6396-6403.
3. Hussain M, Tangen CM, Higano C, et al. Absolute proscare-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990.
4. Basch F.M, Somerfield MR, Beer TM, et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on northormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol. 2007;25:53113-5318.
5. Oefelein MG, Ricchiuti VS, Conrad PW, et al. Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology. Jul 2002;60(1):120-124.
6. Sartor AO, Tangen CM, Hussain MHA, et al. Antiandrogen withdrawal in castrate-refxactory prostate cancer: a Southwest Oncolog Group trial (SWOG 9426). Cancer [in press].
7. Small EJ, Halabi S, Dawson NA. et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-indepedent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025-1033.
8. U.S. FDA: http://www.accessdata.fda.gov/scripts/oder/drugstfda/
9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxanirone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351: 1502-1512.
10. Petrylak DP Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxancrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
11. Nelius T, Klatte T, de Riese W, Filleur, S. Clinical outcome of patients (pts) with taxane-resistant. (TR) hormone-refractory prostate cancer (HRPC) treated with second-line cyclophosphamide (CP)-based metronomic chemotherapy. J Clin Oncol. 2007;25(18S pr 1): Abstract 15647.
12. Zhong F, Kasimis B, Chang N, et al. A phase II trial of epirubicin (E), estramustine phosphate (EP), and celecomb (C) as second line treatment of patients (pts) with hormone resistant prostace cancer (HRPC). J Clin Oncol. 2007;24(18s pt 1): Abstract 14567.
13. Joshua AM, Nordman I, Venkataswaran R, Clarkc S. Stocklet MR, Boyer MJ. Weekly docetaxel as second line treatment after micozantrone for androgen-independent prostate cancer. Intern Med J. 2005;35:468-472.
14. Rosenberg JE, Galsky MD, Rohs NC, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006;106):58-62.
15. Michels J, Montemurro T. Murray N, Kollmannsberger C, Nguyen Chi K. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer. 2006;106:1041-1046.
16. Feinstein TM, Friedland DM, McIntire KE, et al. A Phase II study utilizing oxaliplatin and docetaxel in androgen independent prostate cancer in men treated with up to two prior chemotherapy regimens. J Clin Oncol. 2006;24(18S pt 1): Abstract 14580.
17. Oh WK, Jacobus S, R. Ross, et al. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. Presented at: ASCO Prostate Cancer Symposium. 2007.
18. Lotiot Y. Massard C, Plantade A, et al. A Prospective study of carboplatin-etoposide in docetaxel-pretreated patients with hormone-refractory prostate cancer (HRPC): Clinical activity and correlation with neuroendocrine features. J Clin Oncol. 2007;25(18S pt 1): Abstract 5151.
19. Silva E, 5ilva F. Phase II study of intravenous vinorelbine plus hormone therapy in hormone-refractory prostate cancer. J Clin Oncol. 2006;24(18S pt 1): Abstract 14601.
20. Sewak S, Kosmider S, Ganju V, et al. A phase II study of paditaxel and vinorelbine (Pac-Vin) in hormone-refracrory metastatic prostate cancer (HRPC): a final update. J Clin Oncol. 2007;25(18S pt 1): Abstract 15505.
21. Danila DC, Morris M, Rathkopf D, et al. Preliminary phase II results of abiraterone acetate in patients with castration resistant metastatic prostate cancer after failure of docetaxel-based chemotherapy. Presented at: Chemotherapy Foundation Symposium XXV, 2007; New York, NY.
22. Rosenberg JE, Weinberg VK, Kelly Wk, et al. Activity of second line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556-563.
23. Hatt L, Ciuleanu T, Hainsworth J, et al. Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts). J Clin Oncol. 2006;24(18S pt 1): Abstract 14513,
24. Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. 9-Nitro-camprothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urol Oncol. 2004;22:398-403.
25. Hahn NM, Whalen C, Sweeney CJ. Second-line pemetrexed (P) for the treament of hormone refractory prostate cancer (HRPC): A Hoosler Oncology Group phase II Study: preliminary analysis. J Clin Oncol. 2006;24(18S pt 1): Abstract 4644.
26. Sternberg; CN, Petrylak D, Wities F, et al. Satraplatin (S) demonstrates significant clinical benefirs for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol. 2007;25(18S pt 1): Abstract 5019.
27. US Food and Drug Administration. Guidance for industry: clinical trial end-points for the approval of cancer drugs and biologic. 2007.
28. Berthold DR, Pond G, De Wit R, Eisenberger MA, Tannock IF. Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with Metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. J Clin Oncol. 2006;24(18S pt 1): Abstract 4516.
29. Crawford ED, Pauler DK, Tangen CM, et al. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. J Clin Oncol. 2004;22(14S): Abstract 4505.
30. Moreno J, DeBono JS, Shaffer D, et al. Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC). J Clin Oncol. 2007;25(18S pt 1): Abstract 5016.
31. Halabi S. Ou S, Vogelzang NJ, Scher HI, Small EJ. A novel intermediate endpoint for predicting overall survival in met: with metastatic castration-recurrent prostate cancer (CRPC): An analysis of nine CALGB studies. Presented at: ASCO Prostate Cancer Symposium, 2007.
32. Moyad MA, Kirk TA. National study of patients, caregivers and physicians reveals pain associated with advanced prostate cancer as the primary concern. J Clin Oncol. 2006;24(18S pt 1): Abstract 14505,
33. De Klerk JM, Zonnenberg BA, Biijham GH, et al, Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP. Anticancer Res. 1997;17(3B):1773-1777.
34. Lam MG, de Klerk JM, van Rijk PP. l86Re-HEDP For metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging. 2004;31(suppi 1): S162-170.
35. Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1): S171-178.
36. Nightengale B, Brune M, Blizzard SP, Ashley-Johnson M, Slan S. Strontium chloride Sr 89 for treating pain from metastatic bone disease. Am J Health Syst Pharm. 1995;52:2189-2195.
37. Ogawa K, Mukai T. Arano Y, et al. Development of a rhenium-186-labeled MAG3-cojugated biophosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem. 2005;16:751-757.
38. Pandit-Taskar N. Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45:1358-1365.
39. Sartor O. Radioisotopic treatment of bone pain from metastatic prostate cancer. Curr Oncol Rep. 2003;5:258-262.
40. Sciuto R, Festa A, Pasqualoni R, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat. 2001;66:101-109.
41. Srivastava SC, Atkins HL, Krishnamurthy GT, et al. Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid; a phase I/II clinical study. Clin Cancer Res. 1998;4:61-68.
42. Bruera E, Fainsinger R, MacEachern T. Hanson J, The use of methylphenidate in patients with incident cancer pain receiving regular oplates. A preliminary report. Pain. 1992;50:75-77.
43. Saad F. Gleason DM, Murray R, et al. Long-term efficary of zoledronic acid for die prevention of skeletal Complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882.